• LIPAC Oncology Announces Completion of LiPax Trial for Bladder Cancer americanpharmaceuticalreview
    September 24, 2020
    LIPAC Oncology announced the successful completion of a Phase 2A marker lesion clinical trial designed to predict long-term (two-year) recurrence free survival rates in patients with low-grade highly recurrent Non-Muscle Invasive Bladder Cancer (NMIBC)...
PharmaSources Customer Service